Inhibikase Therapeutics, Inc. (IKT) › Operating IncomeInhibikase Therapeutics, Inc. (IKT) — Operating IncomeAnnual figures by period end, from SEC filings.2020-12-31: -$2.82M2021-12-31: -$14.77M2022-12-31: -$18.13M2023-12-31: -$20.09M2024-12-31: -$28.59M2025-12-31: -$51.97M-$51.97M2020-12-31Operating Income (USD)2025-12-31Period endedOperating IncomeChange YoYSource filing2025-12-31-$51.97M—2026-03-26From 2025-01-012024-12-31-$28.59M—2026-03-26From 2024-01-012023-12-31-$20.09M—2025-03-27From 2023-01-012022-12-31-$18.13M—2024-03-27From 2022-01-012021-12-31-$14.77M—2023-03-31From 2021-01-012020-12-31-$2.82M—2022-03-31From 2020-01-01Other metrics: RevenueCost of RevenueGross ProfitNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)